These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28301096)

  • 1. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
    Johansson S; Rosenbaum DP; Ahlqvist M; Rollison H; Knutsson M; Stefansson B; Elebring M
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):466-475. PubMed ID: 28301096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
    Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
    Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenapanor administration and the activity of the H
    Johansson S; Rosenbaum DP; Palm J; Stefansson B; Knutsson M; Lisbon EA; Hilgendorf C
    Br J Clin Pharmacol; 2017 Sep; 83(9):2008-2014. PubMed ID: 28432691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.
    Johansson S; Leonsson-Zachrisson M; Knutsson M; Spencer AG; Labonté ED; Deshpande D; Kohler J; Kozuka K; Charmot D; Rosenbaum DP
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):448-456. PubMed ID: 27654985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.
    Johansson SA; Knutsson M; Leonsson-Zachrisson M; Rosenbaum DP
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):457-465. PubMed ID: 28339149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
    Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
    Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
    Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
    Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
    de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
    Padhi D; Salfi M; Emery M
    Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
    Berger B; Kaufmann P; Koch A; Dingemanse J
    J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study.
    Yuan G; Chen Y; Li L; Wang X; Wei G; Zeng J; Hui AM; Jiang Y; Zhao H; Diao L; Zhou Y; Xiao Y; Chen M
    Int J Clin Pract; 2024; 2024():1386980. PubMed ID: 38481823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.
    Knöchel J; Panduga V; Nelander K; Heijer M; Lindstedt EL; Ali H; Aurell M; Ödesjö H; Forte P; Connolly K; Ericsson H; MacPhee I
    Br J Clin Pharmacol; 2024 Sep; 90(9):2180-2187. PubMed ID: 38830622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
    Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults.
    Bunn HT; Rosenthal E; Mathur P; McLaughlin M; Proschan M; Vijan A; Aepfelbacher J; Kottilil S; Masur H; Kattakuzhy S; George JM
    J Clin Pharmacol; 2020 Dec; 60(12):1598-1605. PubMed ID: 32578227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin.
    Paulson SK; Wood-Horrall RN; Hoover R; Quintas M; Lawrence LE; Cammarata SK
    Clin Ther; 2017 Jun; 39(6):1182-1190. PubMed ID: 28495029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
    Stroh M; Dishy V; Radziszewski W; Hwang E; Lazarus-Shipitofsky N; Dittrich H; Johnson-Levonas AO; Lutz R; Wagner JA; Lai E
    Am J Ther; 2010; 17(1):53-60. PubMed ID: 20027108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.